Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Common Equity (2016 - 2025)

Historic Common Equity for Orthopediatrics (KIDS) over the last 10 years, with Q3 2025 value amounting to $349.3 million.

  • Orthopediatrics' Common Equity fell 582.61% to $349.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $349.3 million, marking a year-over-year decrease of 582.61%. This contributed to the annual value of $354.6 million for FY2024, which is 595.69% down from last year.
  • Per Orthopediatrics' latest filing, its Common Equity stood at $349.3 million for Q3 2025, which was down 582.61% from $355.5 million recorded in Q2 2025.
  • Orthopediatrics' Common Equity's 5-year high stood at $383.3 million during Q3 2022, with a 5-year trough of $215.0 million in Q1 2022.
  • Its 5-year average for Common Equity is $322.0 million, with a median of $355.5 million in 2025.
  • Its Common Equity has fluctuated over the past 5 years, first tumbled by 860.38% in 2021, then surged by 7352.5% in 2023.
  • Over the past 5 years, Orthopediatrics' Common Equity (Quarter) stood at $225.4 million in 2021, then surged by 68.01% to $378.6 million in 2022, then fell by 0.43% to $377.0 million in 2023, then fell by 5.96% to $354.6 million in 2024, then fell by 1.48% to $349.3 million in 2025.
  • Its Common Equity was $349.3 million in Q3 2025, compared to $355.5 million in Q2 2025 and $347.1 million in Q1 2025.